CVRx, Inc. (CVRX) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged Wrongdoings

NEW YORK, Aug. 19, 2024 (GLOBE NEWSWIRE) — Attorney Advertising–Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of CVRx, Inc. (“CVRx” or “the Company”) (NASDAQ: CVRX). Investors who purchased CVRx securities are encouraged to obtain additional information and assist the investigation by visiting the firm’s site: bgandg.com/CVRX.

Investigation Details

On July 10, 2024, the Centers for Medicare and Medicaid Services (“CMS”) issued proposed payment rates for outpatient and Ambulatory Surgical Center (“ASC”) services. Piper Sandler issued a note indicating that under the CMS rules, reimbursement for CVRx’s heart failure device would fall by 38.1% for ASC services and by 32.9% for hospital outpatient services. Based on this news, shares of CVRx dropped over 38.5% on the same day.

What’s Next?

If you are aware of any facts relating to this investigation or purchased CVRx securities, you can assist this investigation by visiting the firm’s site: bgandg.com/CVRX. You can also contact Peretz Bronstein or his client relations manager, Nathan Miller, of Bronstein, Gewirtz & Grossman, LLC: 332-239-2660.

There is No Cost to You

We represent investors in class actions on a contingency fee basis. That means we will ask the court to reimburse us for out-of-pocket expenses and attorneys’ fees, usually a percentage of the total recovery, only if we are successful.

Why Bronstein, Gewirtz & Grossman

Bronstein, Gewirtz & Grossman, LLC is a nationally recognized firm that represents investors in securities fraud class actions and shareholder derivative suits. Our firm has recovered hundreds of millions of dollars for investors nationwide.

Attorney advertising. Prior results do not guarantee similar outcomes.

Contact

Bronstein, Gewirtz & Grossman, LLC
Peretz Bronstein or Nathan Miller
332-239-2660 | info@bgandg.com


Primary Logo

comtex tracking

COMTEX_456643435/2471/2024-08-19T16:01:30

Scroll to Top